EMA Recommends Romvimza for TGCT Treatment
New Horizons in TGCT Treatment: What the EMA Approval of Romvimza Signals The recent recommendation by the European Medicines Agency (EMA) to approve Romvimza (vimseltinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT) marks a significant leap forward. As a healthcare journalist specializing in rare diseases, I’ve been closely following the developments in this … Read more